Pharmaust Limited (ECQ0) Price & Analysis

3 Followers

ECQ0 Stock Chart & Stats

€0.04

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.04

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.03 - €0.10

Previous CloseN/A

Volume0.00

Average Volume (3M)999.00

Market Cap

€27.95M

Enterprise Value€47.11M

Total Cash (Recent Filing)€7.95M

Total Debt (Recent Filing)€1.62M

Price to Earnings (P/E)―

Beta1.26

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding775,099,500

10 Day Avg. Volume2,225

30 Day Avg. Volume999

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)25.24

Price to Sales (P/S)0.00

P/FCF Ratio-4.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.12

Price Target Upside203.03% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageReported total debt of zero materially reduces near-term refinancing and interest-burden risk, preserving optionality. For a cash-burning biotech, low leverage lessens immediate solvency pressure and gives management more flexibility to pursue financing or partnerships without heavy fixed financing costs.

Cash-flow TransparencyFree cash flow tracking reported losses indicates that operating losses aren't being obscured by working-capital timing, improving forecast reliability. This transparent cash-loss relationship supports clearer planning for financing needs and more disciplined cost management decisions over the medium term.

Prior Commercial Revenue HistoryThe company generated meaningful revenue in 2022–2023, showing prior commercial capability or market access. That historical sales base suggests there are existing assets, channels or products that could be re-monetized, making recovery feasible if execution or clinical progress restores demand.

Bears Say

Revenue CollapseA complete loss of reported revenue is a structural weakness for a small biotech: it removes internal funding sources and increases reliance on external capital. Sustained absence of revenue undermines commercial validation and forces management to prioritize fundraising over growth or R&D investment.

Accelerating Cash BurnRapidly worsening operating cash flow materially increases funding risk and shortens runway, pressuring the company to raise capital or cut critical programs. For a loss-making biotech, accelerating cash burn can force dilution or program delays that impair long-term value creation and competitiveness.

Severe Equity ErosionSubstantial decline in shareholder equity signals that cumulative losses have depleted the capital buffer, reducing financial resilience. With a thin equity base, future adverse results or funding setbacks could quickly impair solvency, limit strategic options and increase the probability of dilutive financings.

Pharmaust Limited News

Neurizon accelerates ALS trial and secures supply deal as funding base strengthens

Pharmaust Limited ( ($AU:NUZ) ) has issued an announcement. Neurizon reported a strong June quarter marked by rapid...

2d ago

Neurizon Secures $17.5m Non-Dilutive R&D Financing to Fund ALS Trial

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has entered a strategic R&D...

2d ago

Neurizon to Outline ALS Trial Progress and NUZ-001 Strategy at Melbourne Investor Briefing

Pharmaust Limited ( ($AU:NUZ) ) has shared an update. Neurizon Therapeutics Limited has scheduled an investor briefing in...

4d ago

Neurizon director Marcus Hughes lifts stake with June share purchases

Pharmaust Limited ( ($AU:NUZ) ) has shared an announcement. Neurizon Therapeutics Limited has reported a change in the...

1M ago

Neurizon Therapeutics Plans Equity Placement of 461,538 Shares

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an announcement. Neurizon Therapeutics Limited has notified the ASX of a...

1M ago

Neurizon options lapse as 5 million NUZAP securities expire unexercised

Pharmaust Limited ( ($AU:NUZ) ) has provided an update. Neurizon Therapeutics Limited has confirmed the cessation of 5,000,000...

1M ago

Neurizon strengthens NUZ-001 ALS case with new mechanistic data at BIO 2026

Pharmaust Limited ( ($AU:NUZ) ) has issued an update. Neurizon Therapeutics has unveiled new preclinical mechanism-of-action data for...

1M ago

Neurizon Therapeutics Seeks ASX Quotation for 9.7 Million New Shares

Pharmaust Limited ( ($AU:NUZ) ) has issued an announcement. Neurizon Therapeutics Limited has applied for quotation on the...

1M ago

Neurizon Secures Long-Term Elanco Supply Deal for Lead ALS Drug NUZ-001

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an update. Neurizon Therapeutics has signed a long-term supply agreement with...

2M ago

Neurizon Therapeutics Seeks ASX Quotation for 7.7 Million New Shares

The latest update is out from Pharmaust Limited ( ($AU:NUZ) ). Neurizon Therapeutics Limited has applied to the...

2M ago

ECQ0 FAQ

What was Pharmaust Limited’s price range in the past 12 months?

Pharmaust Limited lowest stock price was €0.03 and its highest was €0.10 in the past 12 months.

What is Pharmaust Limited’s market cap?

Pharmaust Limited’s market cap is €27.95M.

When is Pharmaust Limited’s upcoming earnings report date?

Pharmaust Limited’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.

How were Pharmaust Limited’s earnings last quarter?

Pharmaust Limited released its earnings results on Feb 24, 2026. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.

Is Pharmaust Limited overvalued?

According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaust Limited pay dividends?

Pharmaust Limited does not currently pay dividends.

What is Pharmaust Limited’s EPS estimate?

Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaust Limited have?

Pharmaust Limited has 775,099,500 shares outstanding.

What happened to Pharmaust Limited’s price movement after its last earnings report?

Pharmaust Limited reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.333%.

Which hedge fund is a major shareholder of Pharmaust Limited?

Currently, no hedge funds are holding shares in DE:ECQ0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharmaust Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-6.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharmaust Limited

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Pharmaust Limited (ECQ0) Earnings & Revenues

Historic Earnings Reports

ECQ0 Stock 12 Month Forecast

Average Price Target

€0.12

▲(203.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.1212138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.1212138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.1212138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.028,0.03517029230769231,0.04234058461538462,0.04951087692307692,0.05668116923076923,0.06385146153846154,0.07102175384615385,0.07819204615384615,0.08536233846153846,0.09253263076923077,0.09970292307692308,0.10687321538461537,0.11404350769230769,{"y":0.1212138,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.028,0.03517029230769231,0.04234058461538462,0.04951087692307692,0.05668116923076923,0.06385146153846154,0.07102175384615385,0.07819204615384615,0.08536233846153846,0.09253263076923077,0.09970292307692308,0.10687321538461537,0.11404350769230769,{"y":0.1212138,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.028,0.03517029230769231,0.04234058461538462,0.04951087692307692,0.05668116923076923,0.06385146153846154,0.07102175384615385,0.07819204615384615,0.08536233846153846,0.09253263076923077,0.09970292307692308,0.10687321538461537,0.11404350769230769,{"y":0.1212138,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.088,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.075,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.058,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.073,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.052,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.044,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.047,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.048,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.039,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.057,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.027,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.028,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >